10 Best Weight Loss Drug Stocks to Buy According to Analysts

8. Viatris Inc. (NASDAQ:VTRS)

Price Target Upside: 21.51% 

Viatris Inc. (NASDAQ:VTRS) stands eighth among the 10 best weight loss drugs to buy according to analysts. It develops and distributes generic and branded medicines across 165+ countries. With a portfolio of over 1,400 approved molecules, it serves various therapeutic areas, including cardiovascular and respiratory conditions. The company’s unique hybrid model bridges generics and branded drugs, allowing it to offer affordable, high-quality medicines while adapting to diverse global healthcare markets.

Viatris Inc. (NASDAQ:VTRS) is making significant strides in the weight loss market by developing generic versions of Novo Nordisk’s popular weight loss drugs, Ozempic and Wegovy, both containing semaglutide. The company has submitted applications for these generics to regulatory authorities, signaling its commitment to providing more affordable alternatives. These applications are currently under review.

Viatris Inc. (NASDAQ:VTRS) is also challenging Novo Nordisk’s patents on semaglutide. The company successfully initiated a review of U.S. Patent No. 10,335,462, which covers dosage regimens for semaglutide in diabetes and obesity treatment. The U.S. Patent and Trademark Office will conduct an inter partes review, with a decision expected by October 2025. If successful, the company’s generic version could significantly lower costs and expand access to weight loss medications.

Despite competition from newer drugs like Eli Lilly’s Mounjaro (tirzepatide), Viatris Inc. (NASDAQ:VTRS) believes semaglutide still has a strong market presence, similar to how older drugs like Trulicity remained relevant. Clinical trials have shown that semaglutide leads to substantial weight loss, with 77.1% of participants achieving at least a 5% reduction in weight. A generic version could provide a cost-effective option for a wider population.